Is Thymosin α-1 legal?
Regulatory status · reviewed June 1, 2026
Approved in several countries (Zadaxin); not FDA-approved.
What that status actually means.
Thymosin α-1 is in registered human clinical trials but has not been approved. Investigational status means a regulator has permitted the compound to be studied in humans under a controlled protocol, which is a meaningful step, and specifically not a finding that it is safe or effective.
Material sold commercially is not trial material. Compounds in clinical development are supplied to trial sites under controlled conditions, so anything available to buy is a separate product of unverified identity and purity that happens to share a name.
Investigational compounds fail regularly, including at late stages and including after promising early results. A drug in Phase 3 has not yet cleared the bar that most candidates do not clear.
The regulatory record for Thymosin α-1.
Thymalfasin (Zadaxin) is approved and marketed as a prescription drug in roughly 30-plus countries (including China, Italy, and parts of Asia, Latin America, and the Middle East), chiefly for chronic hepatitis B and as an immune adjunct, but it is NOT approved by the US FDA or centrally by the EMA; in the US it has held orphan-drug designations and been studied investigationally. In US compounding, FDA placed thymosin alpha-1 in Category 2 of the interim 503A bulk substances list in 2023 (citing safety/data concerns), and in 2024 it was removed from Category 2 after its nomination was withdrawn, leaving it without a clear compounding pathway.
Compounding, sport, and jurisdiction.
Three separate regimes govern a compound like this one, and they move independently. US compounding eligibility runs through sections 503A and 503B and the FDA lists that sit under them, which are revised over time as the agency evaluates individual substances. A compound can be widely compounded one year and removed from eligibility the next.
Anti-doping status is set separately by WADA and does not track FDA approval at all. The prohibited list covers peptide hormones, growth factors, related substances and mimetics as categories, which means an unapproved research compound can be firmly prohibited in competition while an approved medicine is permitted with the right documentation.
And none of this is global. Approval, scheduling and import rules differ by country, and a compound registered as a medicine in one jurisdiction can be entirely unapproved in another. Several compounds on this site are prescription medicines in one country and research chemicals in the next.
This page describes publicly documented regulatory status. It is not legal advice and does not tell you whether obtaining or using this compound is lawful in your jurisdiction or your circumstances.
FAQ.
Is Thymosin α-1 FDA-approved?
No. Approved in several countries (Zadaxin); not FDA-approved.
Is it legal to buy Thymosin α-1?
It is commonly sold labelled for laboratory research use, which is a posture the seller adopts. That labelling does not address whether possessing or administering it is lawful where you are, and the answer varies by jurisdiction.
Can a compounding pharmacy prepare Thymosin α-1?
US compounding is governed by sections 503A and 503B, and the substances eligible for it are tracked on specific FDA lists that change over time. A compound being prepared by a pharmacy is not equivalent to FDA approval, and eligibility for compounding is not permanent.
Is Thymosin α-1 banned in sport?
Anti-doping status is set by WADA and is separate from FDA status. Peptide hormones, growth factors, and their releasing factors are broadly covered by the prohibited list, so a compound can be entirely unapproved as a medicine and still prohibited in competition. Athletes should check the current list directly rather than infer status from regulatory position.
Cite this page
PepCue. “Is Thymosin α-1 legal? FDA and regulatory status.” PepCue, reviewed June 1, 2026. https://www.pepcue.app/legal/thymosin-alpha-1.